📊 MYGN Key Takeaways
Is Myriad Genetics Inc. (MYGN) a Good Investment?
Myriad Genetics faces severe fundamental deterioration with operating losses of -$387.2M and net losses worsening 187.4% YoY despite generating $824.5M in revenue. The company burns -$40.5M annually in free cash flow while producing minimal operating cash flow ($1.8M), indicating structural operational challenges not explained by cyclical weakness. With only ~3.7 years of cash runway at current burn rates and no visible path to profitability, shareholder value is being systematically destroyed.
Despite strong gross margins and a solid liquidity profile, Myriad Genetics is generating steep operating and net losses with markedly negative year-over-year earnings trends. Free cash flow remains negative and operating income deeply in the red, implying core operations are not yet self-funding. Until sustained operating margin improvement and positive operating cash flow are evident, fundamentals skew unfavorable.
Why Buy Myriad Genetics Inc. Stock? MYGN Key Strengths
- High gross margin of 69.9% demonstrates strong underlying unit economics for core diagnostic business
- Strong liquidity position with 2.49x current ratio and $149.6M in cash providing near-term survival cushion
- Conservative debt structure with 0.33x debt-to-equity ratio limiting refinancing risk
- High gross margin indicating pricing power and IP
- Strong liquidity with low leverage (current and quick ratios >2x, D/E 0.33x)
- Cash balance exceeds long‑term debt, providing runway
MYGN Stock Risks: Myriad Genetics Inc. Investment Risks
- Negative free cash flow of -$40.5M annually is unsustainable; company will exhaust cash reserves in ~3-4 years without profitability return
- Massive operating losses (-$387.2M) with deteriorating net income (-187.4% YoY) indicate fundamental operational dysfunction, not temporary headwinds
- Severely negative return metrics (ROE -99.4%, ROA -51.8%) demonstrate systematic value destruction despite $824.5M revenue base
- Operating cash flow of only $1.8M against $824.5M revenue suggests severe working capital or operational challenges
- Persistent operating losses and negative net margin erode equity
- Weak revenue trend and potential mix/reimbursement pressure
- Turnaround execution risk leading to continued cash burn
Key Metrics to Watch
- Operating expense trajectory and achievement of operating breakeven timeline
- Operating cash flow and free cash flow trends - critical for sustainability assessment
- Cash burn rate and remaining cash runway - determines financial viability window
- Revenue stability and gross margin maintenance as company navigates cost restructuring
- Operating cash flow (TTM)
- Operating margin (TTM)
Myriad Genetics Inc. (MYGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.49x current ratio provides a solid financial cushion.
MYGN Profit Margin, ROE & Profitability Analysis
MYGN vs Healthcare Sector: How Myriad Genetics Inc. Compares
How Myriad Genetics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Myriad Genetics Inc. Stock Overvalued? MYGN Valuation Analysis 2026
Based on fundamental analysis, Myriad Genetics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Myriad Genetics Inc. Balance Sheet: MYGN Debt, Cash & Liquidity
MYGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Myriad Genetics Inc.'s revenue has remained relatively flat over the 5-year period, with a 2% decline. The most recent EPS of $-3.18 indicates the company is currently unprofitable.
MYGN Revenue Growth, EPS Growth & YoY Performance
MYGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $205.7M | -$100.0K | $-0.24 |
| Q2 2025 | $211.5M | -$100.0K | $-0.41 |
| Q1 2025 | $195.9M | -$100.0K | $0.00 |
| Q3 2024 | $191.9M | -$22.1M | $-0.24 |
| Q2 2024 | $183.5M | -$26.0M | $-0.41 |
| Q1 2024 | $181.2M | -$26.0M | $-0.29 |
| Q3 2023 | $156.4M | -$14.1M | $-0.43 |
| Q2 2023 | $179.3M | -$14.1M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Myriad Genetics Inc. Dividends, Buybacks & Capital Allocation
MYGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Myriad Genetics Inc. (CIK: 0000899923)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MYGN
What is the AI rating for MYGN?
Myriad Genetics Inc. (MYGN) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MYGN's key strengths?
Claude: High gross margin of 69.9% demonstrates strong underlying unit economics for core diagnostic business. Strong liquidity position with 2.49x current ratio and $149.6M in cash providing near-term survival cushion. ChatGPT: High gross margin indicating pricing power and IP. Strong liquidity with low leverage (current and quick ratios >2x, D/E 0.33x).
What are the risks of investing in MYGN?
Claude: Negative free cash flow of -$40.5M annually is unsustainable; company will exhaust cash reserves in ~3-4 years without profitability return. Massive operating losses (-$387.2M) with deteriorating net income (-187.4% YoY) indicate fundamental operational dysfunction, not temporary headwinds. ChatGPT: Persistent operating losses and negative net margin erode equity. Weak revenue trend and potential mix/reimbursement pressure.
What is MYGN's revenue and growth?
Myriad Genetics Inc. reported revenue of $824.5M.
Does MYGN pay dividends?
Myriad Genetics Inc. does not currently pay dividends.
Where can I find MYGN SEC filings?
Official SEC filings for Myriad Genetics Inc. (CIK: 0000899923) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MYGN's EPS?
Myriad Genetics Inc. has a diluted EPS of $-3.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MYGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Myriad Genetics Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MYGN stock overvalued or undervalued?
Valuation metrics for MYGN: ROE of -99.4% (sector avg: 15%), net margin of -44.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MYGN stock in 2026?
Our dual AI analysis gives Myriad Genetics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MYGN's free cash flow?
Myriad Genetics Inc.'s operating cash flow is $1.8M, with capital expenditures of $42.3M. FCF margin is -4.9%.
How does MYGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -44.4% (avg: 12%), ROE -99.4% (avg: 15%), current ratio 2.49 (avg: 2).